Korea S.E.
06:00:00 2024-04-25 pm EDT
5-day change
1st Jan Change
485
KRW
-1.62%
+3.19%
-3.96%
Next Bt Co., Ltd. announced that it has received KRW 9 billion in funding from KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Meritz Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd.
On March 27, 2019, Next Bt Co., Ltd. (KOSDAQ:A065170) closed the transaction.
Youngchul Park completed the acquisition of 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation.
Mar. 27
CI
BL Pharmtech Corp. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 20
CI
Youngchul Park agreed to acquire 24.43% stake in BL Pharmtech Corp. (KOSDAQ : A065170) from Bioleaders Corporation for KRW 9.3 billion.
Mar. 11
CI
BL Pharmtech agreed to acquire an additional 30.89% stake in Anyone F&C Co., Ltd. for KRW 9 billion
Feb. 14
CI
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
Dec. 28
CI
BL Pharmtech Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Nov. 14
CI
BL Pharmtech Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
23-08-11
CI
BL Pharmtech Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-05-12
CI
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
22-11-11
CI
Next Bt Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-05-13
CI
Next Bt Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
22-03-22
CI
Next Bt Co., Ltd. announced that it has received KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
21-11-30
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 6 billion in funding from Bioleaders Corporation, Dk Life Science Co., Ltd. and other investors
21-11-28
CI
Next Bt Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
21-11-12
CI
Next Bt Co., Ltd. announced that it has received KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
21-03-30
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 10.4 billion in funding from Samsung Securities Co., Ltd., KB Securities Co., Ltd., NH Investment & Securities Co., Ltd., Korea Investment & Securities Co., Ltd., Mirae Asset Venture Investment Co., Ltd., Mirae Asset Securities Co., Ltd.
21-03-28
CI
Next Bt Co., Ltd. completed the acquisition of the remaining 77.7% stake in TCM Biosciences Inc..
20-07-16
CI
Next Bt Co., Ltd. agreed to acquire the remaining 77.7% stake in TCM Biosciences Inc. for KRW 37 billion.
20-04-19
CI
Next Bt Co., Ltd. acquired 22.25% stake in TCM Biosciences Inc. from Park Young Chul for KRW 15.9 billion.
20-03-30
CI
Next Bt Co., Ltd. announced that it has received KRW 6.5 billion in funding
20-01-06
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 6.5 billion in funding
20-01-02
CI
Next Bt Co., Ltd. announced that it has received KRW 9 billion in funding from KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Meritz Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd.
19-03-26
CI
Next Bt Co., Ltd. announced that it expects to receive KRW 9 billion in funding from KDB Capital Corporation, Investment Arm, IBK Capital Corporation, Meritz Securities Co., Ltd., Investment Arm, Mirae Asset Daewoo Co., Ltd.
19-03-24
CI
Next Bt Co., Ltd. acquired 2.76% stake in Bioleaders Corporation for KRW 8 billion.
18-04-23
CI
BioLeaders Corporation acquired additional 21.68% stake in Next Bt Co., Ltd..
18-03-27
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
BL PharmTech Corp, formerly Next BT Co Ltd, is a Korea-based company primarily engaged in the manufacture and sale of health foods. The Company operates its business through four segments. The Health Functional Food Business segment is engaged in the manufacture and sale of products such as red ginsengs, diet foods and vitamins. The Cosmetics Business segment is engaged in the manufacture and sale of anti-aging skincare products and, among others. The Diagnostic and Medical Business segment is engaged in the manufacture and sale of diagnostic kits and other products. The Other segment is engaged in the distribution of health foods and other products.
More about the company
1st Jan change
Capi.
-3.96% 31.35M +8.20% 7.78B +10.20% 6.52B -8.10% 3.67B -13.13% 3.44B -14.57% 1.17B +8.34% 934M -42.27% 879M -18.90% 836M -16.45% 802M
Special Foods & Wellbeing Products
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
BL PHARMTECH CORP. 
